Literature DB >> 7964845

Requirements for safety and quality of intravenous immunoglobulin G preparations.

G H Rütter1.   

Abstract

The increasing use of intravenous immunoglobulin-G preparations (IVIg) calls for evaluation of the requirements for quality and freedom from infection. The WHO Requirements dating from 1982 have been surpassed by the majority of IVIg preparations. Three methods are used for ensuring safety from infection: the restrictive choice of donor, the precise introductory screening of every individual blood or plasma donation, and the additional active virus inactivation procedures that surpass the virus elimination of, for example, the Cohn-fractionation method. Although it is highly improbable that IVIg can transfer infections, this possibility cannot be completely ruled out even when all the GMP (good manufacturing practice) rules are observed most carefully. Increased safety from infection would be provided if blood and plasma donations were obtained nationally from unpaid voluntary donors and if an additional active viral inactivation procedure was introduced.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964845      PMCID: PMC1016713          DOI: 10.1136/jnnp.57.suppl.2

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  4 in total

Review 1.  Effect of ethanol on viruses.

Authors:  J J Morgenthaler
Journal:  Curr Stud Hematol Blood Transfus       Date:  1989

Review 2.  Clinical uses of intravenous immunoglobulins.

Authors:  S A Berkman; M L Lee; R P Gale
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

Review 3.  The development of virus-free labile blood derivatives--a review.

Authors:  A M Prince; B Horowitz; M S Horowitz; E Zang
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

Review 4.  Clinical uses of intravenous immunoglobulins.

Authors:  S A Berkman; M L Lee; R P Gale
Journal:  Semin Hematol       Date:  1988-04       Impact factor: 3.851

  4 in total
  3 in total

1.  Atypical C-ANCA following high dose intravenous immunoglobulin.

Authors:  S Jolles; S Deacock; W Turnbull; R Silvestrini; C Bunn; P White; M Ward
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

2.  Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.

Authors:  R I Schiff; L W Williams; R P Nelson; R H Buckley; W Burks; R A Good
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

3.  Immune globulin intravenous (human), 5% liquid gammaplex: for replacement therapy of primary humoral immunodeficiency.

Authors: 
Journal:  P T       Date:  2011-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.